TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 40nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 40nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 50nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 50nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 50nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 50nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 60nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 120nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 150nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 160nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 160nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 200nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 250nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 310nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 370nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 370nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 410nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 410nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 410nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 490nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 500nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 700nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1.40E+3nMAssay Description:Tested for 50% of inhibition of Osteoclastic acid phosphatase (OAP) activity, determined using dose-response curveMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 3.00E+3nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
TargetPolyunsaturated fatty acid 5-lipoxygenase(Rattus norvegicus)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 4.83E+3nMAssay Description:In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assayMore data for this Ligand-Target Pair
Affinity DataIC50: 6.00E+3nMAssay Description:Tested for 50% of inhibition of Osteoclastic acid phosphatase (OAP) activity, determined using dose-response curveMore data for this Ligand-Target Pair
Affinity DataIC50: 6.00E+3nMAssay Description:Inhibition of alpha-4 beta7/MAdCAM mediated cell adhesion was evaluated using B-cell lymphoma RPMI 8866 cellsMore data for this Ligand-Target Pair
Affinity DataIC50: 6.30E+3nMAssay Description:Tested for 50% of inhibition of Osteoclastic acid phosphatase (OAP) activity, determined using dose-response curveMore data for this Ligand-Target Pair
Affinity DataIC50: 7.00E+3nMAssay Description:Inhibition of alpha-4 beta7/MAdCAM mediated cell adhesion was evaluated using B-cell lymphoma RPMI 8866 cellsMore data for this Ligand-Target Pair
Affinity DataIC50: 7.00E+3nMAssay Description:Inhibition of alpha-4 beta7/MAdCAM mediated cell adhesion was evaluated using B-cell lymphoma RPMI 8866 cellsMore data for this Ligand-Target Pair
Affinity DataIC50: 9.00E+3nMAssay Description:Inhibition of human prostatic acid phosphatase was determined as inhibition of the hydrolysis of tyrosine phosphateMore data for this Ligand-Target Pair
Affinity DataIC50: 9.00E+3nMAssay Description:Inhibition of alpha-4 beta7/MAdCAM mediated cell adhesion was evaluated using B-cell lymphoma RPMI 8866 cellsMore data for this Ligand-Target Pair
Affinity DataIC50: 9.30E+3nMAssay Description:Tested for 50% of inhibition of Osteoclastic acid phosphatase (OAP) activity, determined using dose-response curveMore data for this Ligand-Target Pair
Affinity DataIC50: 1.10E+4nMAssay Description:Tested for 50% of inhibition of Osteoclastic acid phosphatase (OAP) activity, determined using dose-response curveMore data for this Ligand-Target Pair
Affinity DataIC50: 1.14E+4nMAssay Description:Tested for 50% of inhibition of Osteoclastic acid phosphatase (OAP) activity, determined using dose-response curveMore data for this Ligand-Target Pair
Affinity DataIC50: 1.30E+4nMAssay Description:Inhibition of canine cardiac fraction III cAMP phosphodiesterase (PDE 3) at 1.875 mg/kg intravenous doseMore data for this Ligand-Target Pair
Affinity DataIC50: 1.40E+4nMAssay Description:Inhibition of human prostatic acid phosphatase was determined as inhibition of the hydrolysis of tyrosine phosphateMore data for this Ligand-Target Pair
Affinity DataIC50: 1.40E+4nMAssay Description:Inhibition of human prostatic acid phosphatase was determined as inhibition of the hydrolysis of tyrosine phosphateMore data for this Ligand-Target Pair
Affinity DataIC50: 1.40E+4nMAssay Description:Inhibitory activity against canine cardiac fraction III cyclic AMP phosphodiesterase (PDE III) at 8.75 mg/kg intravenous doseMore data for this Ligand-Target Pair
Affinity DataIC50: 1.50E+4nMAssay Description:Inhibition of human prostatic acid phosphatase was determined as inhibition of the hydrolysis of tyrosine phosphateMore data for this Ligand-Target Pair
Affinity DataIC50: 1.60E+4nMAssay Description:Inhibition of human prostatic acid phosphatase was determined as inhibition of the hydrolysis of tyrosine phosphateMore data for this Ligand-Target Pair
Affinity DataIC50: 1.70E+4nMAssay Description:Inhibition of canine cardiac fraction III cAMP phosphodiesterase (PDE 3) at 0.875 mg/kg intravenous doseMore data for this Ligand-Target Pair
Affinity DataIC50: 1.70E+4nMAssay Description:Inhibition of human prostatic acid phosphatase was determined as inhibition of the hydrolysis of tyrosine phosphateMore data for this Ligand-Target Pair
Affinity DataIC50: 1.80E+4nMAssay Description:Inhibition of canine cardiac fraction III cAMP phosphodiesterase (PDE 3) at 1.875 mg/kg intravenous doseMore data for this Ligand-Target Pair
Affinity DataIC50: 1.80E+4nMAssay Description:Inhibitory activity against canine cardiac fraction III cyclic AMP phosphodiesterase (PDE III) at 8.75 mg/kg intravenous doseMore data for this Ligand-Target Pair
Affinity DataIC50: 2.10E+4nMAssay Description:Tested for 50% of inhibition of Osteoclastic acid phosphatase (OAP) activity, determined using dose-response curveMore data for this Ligand-Target Pair
Affinity DataIC50: 2.10E+4nMAssay Description:Tested for 50% of inhibition of Osteoclastic acid phosphatase (OAP) activity, determined using dose-response curveMore data for this Ligand-Target Pair
Affinity DataIC50: 2.20E+4nMAssay Description:Inhibitory activity against canine cardiac fraction III cyclic AMP phosphodiesterase (PDE III) at 8.75 mg/kg intravenous doseMore data for this Ligand-Target Pair
Affinity DataIC50: 2.20E+4nMAssay Description:Inhibition of human prostatic acid phosphatase was determined as inhibition of the hydrolysis of tyrosine phosphateMore data for this Ligand-Target Pair
Affinity DataIC50: 2.50E+4nMAssay Description:Inhibitory activity against canine cardiac fraction III cyclic AMP phosphodiesterase (PDE III) at 8.75 mg/kg intravenous doseMore data for this Ligand-Target Pair